Cargando…
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer
Personalized medicine has emerged as the future of cancer care to ensure that patients receive individualized treatment specific to their needs. In order to provide such care, molecular techniques that enable oncologists to diagnose, treat, and monitor tumors are necessary. In the field of lung canc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342606/ https://www.ncbi.nlm.nih.gov/pubmed/27589834 http://dx.doi.org/10.18632/oncotarget.11717 |
_version_ | 1782513219442573312 |
---|---|
author | Bennett, Catherine W. Berchem, Guy Kim, Yeoun Jin El-Khoury, Victoria |
author_facet | Bennett, Catherine W. Berchem, Guy Kim, Yeoun Jin El-Khoury, Victoria |
author_sort | Bennett, Catherine W. |
collection | PubMed |
description | Personalized medicine has emerged as the future of cancer care to ensure that patients receive individualized treatment specific to their needs. In order to provide such care, molecular techniques that enable oncologists to diagnose, treat, and monitor tumors are necessary. In the field of lung cancer, cell free DNA (cfDNA) shows great potential as a less invasive liquid biopsy technique, and next-generation sequencing (NGS) is a promising tool for analysis of tumor mutations. In this review, we outline the evolution of cfDNA and NGS and discuss the progress of using them in a clinical setting for patients with lung cancer. We also present an analysis of the role of cfDNA as a liquid biopsy technique and NGS as an analytical tool in studying EGFR and MET, two frequently mutated genes in lung cancer. Ultimately, we hope that using cfDNA and NGS for cancer diagnosis and treatment will become standard for patients with lung cancer and across the field of oncology. |
format | Online Article Text |
id | pubmed-5342606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53426062017-03-24 Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer Bennett, Catherine W. Berchem, Guy Kim, Yeoun Jin El-Khoury, Victoria Oncotarget Review Personalized medicine has emerged as the future of cancer care to ensure that patients receive individualized treatment specific to their needs. In order to provide such care, molecular techniques that enable oncologists to diagnose, treat, and monitor tumors are necessary. In the field of lung cancer, cell free DNA (cfDNA) shows great potential as a less invasive liquid biopsy technique, and next-generation sequencing (NGS) is a promising tool for analysis of tumor mutations. In this review, we outline the evolution of cfDNA and NGS and discuss the progress of using them in a clinical setting for patients with lung cancer. We also present an analysis of the role of cfDNA as a liquid biopsy technique and NGS as an analytical tool in studying EGFR and MET, two frequently mutated genes in lung cancer. Ultimately, we hope that using cfDNA and NGS for cancer diagnosis and treatment will become standard for patients with lung cancer and across the field of oncology. Impact Journals LLC 2016-08-30 /pmc/articles/PMC5342606/ /pubmed/27589834 http://dx.doi.org/10.18632/oncotarget.11717 Text en Copyright: © 2016 Bennett et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Bennett, Catherine W. Berchem, Guy Kim, Yeoun Jin El-Khoury, Victoria Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer |
title | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer |
title_full | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer |
title_fullStr | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer |
title_full_unstemmed | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer |
title_short | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer |
title_sort | cell-free dna and next-generation sequencing in the service of personalized medicine for lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342606/ https://www.ncbi.nlm.nih.gov/pubmed/27589834 http://dx.doi.org/10.18632/oncotarget.11717 |
work_keys_str_mv | AT bennettcatherinew cellfreednaandnextgenerationsequencingintheserviceofpersonalizedmedicineforlungcancer AT berchemguy cellfreednaandnextgenerationsequencingintheserviceofpersonalizedmedicineforlungcancer AT kimyeounjin cellfreednaandnextgenerationsequencingintheserviceofpersonalizedmedicineforlungcancer AT elkhouryvictoria cellfreednaandnextgenerationsequencingintheserviceofpersonalizedmedicineforlungcancer |